ArticleExperimental hematology & oncology2022

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.

Guillaume Cartron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.